Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsors and Collaborators: |
Sorlandet Hospital HF Ullevaal University Hospital |
---|---|
Information provided by: | Sorlandet Hospital HF |
ClinicalTrials.gov Identifier: | NCT00679237 |
Secondary prevention in coronary heart disease
Condition | Intervention |
---|---|
Coronary Heart Disease |
Behavioral: smoking cessation Drug: betablocker, diuretics, ACEI, ARB, moxonidine Drug: statins (simvastatin, atorvastatin), ezetimib Behavioral: training Biological: influenzavaccine Drug: metformin, glimepiride, insulin |
Study Type: | Interventional |
Study Design: | Prevention, Randomized, Open Label, Placebo Control, Parallel Assignment, Efficacy Study |
Official Title: | Secondary Prevention in Coronary Heart Disease |
Estimated Enrollment: | 950 |
Study Start Date: | September 2007 |
Estimated Study Completion Date: | December 2012 |
Estimated Primary Completion Date: | December 2012 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
I: Active Comparator |
Behavioral: smoking cessation
NRT and varenicline
Drug: betablocker, diuretics, ACEI, ARB, moxonidine
blood pressure control according to ESC guidelines
Drug: statins (simvastatin, atorvastatin), ezetimib
Cholesterol reduction according to ESC guidelines
Behavioral: training
daily walking
Biological: influenzavaccine
vaccine (FLuarix, Influvac etc)
Drug: metformin, glimepiride, insulin
s.glucose control according to ESC guidelines
|
Controll: No Intervention
without intervention
|
Risk factor reduction in coronary heart disease
Ages Eligible for Study: | 18 Years to 79 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contact: Jarle Jortveit, MD | 004737014000 | jarle.jortveit@sshf.no |
Norway | |
Sorlandet Hospital | Recruiting |
Arendal, Norway | |
Contact: Jarle Jortveit, MD 00473714000 jarle.jortveit@sshf.no |
Study Chair: | Serena Tonstad, dr.med. | Ullevaal University Hospital |
Responsible Party: | Sorlandet Hospital HF ( Jarle Jortveit ) |
Study ID Numbers: | S-07041a (REK) |
Study First Received: | July 5, 2007 |
Last Updated: | May 14, 2008 |
ClinicalTrials.gov Identifier: | NCT00679237 |
Health Authority: | Norway: The National Committees for Research Ethics in Norway; Norway: Norwegian Social Science Data Services |
Arterial Occlusive Diseases Heart Diseases Simvastatin Myocardial Ischemia Metformin Vascular Diseases Ezetimibe Ischemia |
Arteriosclerosis Insulin Coronary Disease Glimepiride Moxonidine Neoplasm Metastasis Coronary Artery Disease Atorvastatin |
Antimetabolites Molecular Mechanisms of Pharmacological Action Immunologic Factors Antilipemic Agents Physiological Effects of Drugs Enzyme Inhibitors Cardiovascular Agents Anticholesteremic Agents |
Hydroxymethylglutaryl-CoA Reductase Inhibitors Antihypertensive Agents Immunosuppressive Agents Pharmacologic Actions Hypoglycemic Agents Therapeutic Uses Cardiovascular Diseases Anti-Arrhythmia Agents |